(Q80543535)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15356668%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15356668%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15356668%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

H Hauner

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15356668%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 November 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15356668%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15356668%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15356668%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

1357-1364

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15356668%20AND%20SRC:MED&resulttype=core&format=json

Role of insulin resistance in human disease (syndrome X): an expanded definition

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

The adipocyte and hemostatic balance in obesity: studies of PAI-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Plasminogen-activator inhibitor type 1 and coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Synthesis and secretion of plasminogen activator inhibitor-1 by human preadipocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Culture of human adipose tissue explants leads to profound alteration of adipocyte gene expression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

The role of TNF-alpha in human adipose tissue: prevention of weight gain at the expense of insulin resistance?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Increased adipose angiotensinogen gene expression in human obesity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Beta-Adrenoceptor agonists and other cAMP elevating agents suppress PAI-1 production of human adipocytes in primary culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Cellular Carbonyl Stress Enhances the Expression of Plasminogen Activator Inhibitor-1 in Rat White Adipocytes via Reactive Oxygen Species-dependent Pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Obesity, haemostasis and the fibrinolytic system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

The influence of weight loss on fibrinolytic and metabolic parameters in obese children and adolescents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Weight change and blood coagulability and fibrinolysis in healthy obese women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Evaluation of clotting and fibrinolytic activation after protracted physical exercise.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Association between physical activity and endogenous fibrinolysis in peripheral arterial disease: a cross-sectional study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Influence of a rehabilitation sports programme on the fibrinolytic activity of patients after myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 gene during very low calorie diet in obese subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Autocrine regulation of human preadipocyte migration by plasminogen activator inhibitor-1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802778

7 January 2021

Identifiers

DOI

10.1038/SJ.IJO.0802778

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15356668%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference